Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
$6.11
+2.5%
$9.09
$5.50
$11.99
$116.93MN/A57,078 shs248,403 shs
(ANTX) stock logo
ANTX
(ANTX)
$1.07
-12.7%
$0.00
$0.87
$3.07
$33.76M0.15368,036 shs83,337 shs
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$0.95
+15.2%
$0.69
$0.28
$2.45
$296.75M16.82 million shs8.89 million shs
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$8.84
-1.1%
$9.13
$7.65
$38.40
$132.38M-0.2672,133 shs60,521 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
0.00%-20.21%-47.54%-11.96%+595,999,900.00%
(ANTX) stock logo
ANTX
(ANTX)
0.00%-1.83%+0.38%-20.45%-50.23%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.00%+9.45%+27.81%+78.15%-51.14%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
0.00%+2.88%+9.21%-16.91%-69.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
2.5459 of 5 stars
3.50.00.00.02.63.30.0
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/AN/AN/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.5585 of 5 stars
3.23.00.00.02.02.50.6
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
3.7367 of 5 stars
2.84.00.00.03.15.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
3.00
Buy$20.50235.52% Upside
(ANTX) stock logo
ANTX
(ANTX)
2.00
Hold$1.5040.85% Upside
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.40
Hold$3.67287.72% Upside
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
1.50
Reduce$15.0069.68% Upside

Current Analyst Ratings Breakdown

Latest ANTX, ACTU, LYEL, and LXRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/24/2025
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$10.00
6/3/2025
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$20.00
5/5/2025
(ANTX) stock logo
ANTX
(ANTX)
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$5.00 ➝ $2.00
4/22/2025
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
4/16/2025
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$20.00 ➝ $20.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/A$0.01 per shareN/A
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/A$4.19 per shareN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$31.08M11.00N/AN/A$0.40 per share2.36
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$60K2,182.01N/AN/A$26.21 per share0.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
-$27.28MN/A0.00N/AN/AN/A-339.73%N/A
(ANTX) stock logo
ANTX
(ANTX)
-$64.73M-$2.04N/AN/AN/AN/A-57.62%-52.08%N/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$200.40M-$0.51N/AN/AN/A-568.04%-103.16%-54.95%7/30/2025 (Estimated)
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$342.99M-$25.00N/AN/AN/A-514,649.22%-73.66%-60.99%8/6/2025 (Estimated)

Latest ANTX, ACTU, LYEL, and LXRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
-$0.26-$0.32-$0.06-$0.32N/AN/A
5/13/2025Q1 2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.10-$0.07+$0.03-$0.07$1.26 million$1.26 million
5/13/2025Q1 2025
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$3.80-$3.60+$0.20-$0.18N/A$0.01 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/AN/A
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/A
0.46
0.46
(ANTX) stock logo
ANTX
(ANTX)
N/A
9.75
9.75
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.48
2.22
2.22
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
N/A
7.49
7.49

Institutional Ownership

CompanyInstitutional Ownership
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/A
(ANTX) stock logo
ANTX
(ANTX)
90.47%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
74.70%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
66.05%

Insider Ownership

CompanyInsider Ownership
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
69.34%
(ANTX) stock logo
ANTX
(ANTX)
20.79%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
13.90%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
22.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
1019.62 million6.02 millionN/A
(ANTX) stock logo
ANTX
(ANTX)
N/A29.88 million23.67 millionNot Optionable
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
140361.49 million311.25 millionOptionable
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
27014.81 million11.51 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Actuate Therapeutics stock logo

Actuate Therapeutics NASDAQ:ACTU

$6.11 +0.15 (+2.52%)
As of 04:00 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

(ANTX) stock logo

(ANTX) NYSE:ANTX

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Lexicon Pharmaceuticals stock logo

Lexicon Pharmaceuticals NASDAQ:LXRX

$0.95 +0.12 (+15.20%)
As of 04:00 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Lyell Immunopharma stock logo

Lyell Immunopharma NASDAQ:LYEL

$8.84 -0.10 (-1.12%)
As of 04:00 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.